Bfl-1-IN-6 TFA salt form · salt · Parent Bfl-1-IN-6 TFA

Bfl-1-IN-6 TFA is a Covalent, Orally Bioavailable, and Selective BFL1 Inhibitor.

For research use only. Not for human or veterinary use.

Target Bcl-2 Family Caspase Apoptosis

Research area Cancer

Purity >98% Stock Inquire

Data Sheet SDS COA

Bfl-1-IN-6 TFA structure

CAS No.: 3106364-91-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
10 mg	USD 760.00	BP-02179A-10mg	In stock	Get quote
25 mg	USD 1,520.00	BP-02179A-25mg	In stock	Get quote
50 mg	USD 2,430.00	BP-02179A-50mg	In stock	Get quote
100 mg	USD 3,800.00	BP-02179A-100mg	In stock	Get quote
250 mg	USD 7,800.00	BP-02179A-250mg	In stock	Get quote

Need another size or custom synthesis? Request a quote.

Description

Bfl-1-IN-6 TFA is a Covalent, Orally Bioavailable, and Selective BFL1 Inhibitor.

Biological activity

In Vitro Bfl-1-IN-6 (Compound 20) TFA induces caspase activation in SUDHL1 cells treated with 0.5 μM AZD5991 (HY-101533) with an EC50 of 350 nM, thereby resulting in decreased cell viability. Bfl-1-IN-6 TFA combined with 0.5 μM AZD5991 reduces the viability of SUDHL1 cells, with an EC50 of 250 nM, and causes no significant off-target toxicity in BFL1-deficient Karpas-422 cells. Bfl-1-IN-6 (0.3-9 μM; 6 h) TFA induces dose-dependent BFL1 stabilization and activation of cleaved caspase-3 in OCILY10 cells, and exhibits targeted apoptotic activity after 6 hours of treatment. In Vivo Bfl-1-IN-6 (Compound 20) (100-300 mg/kg; p.o.; single dose) TFA causes dose-dependent stabilization of BFL1 and activation of cleaved caspase 3 in OCILY10 lymphoma tumor xenografts in mice.

Identifiers

SMILES: C(C(O)=O)(F)(F)F.N([C@@H](C)C1=CC=C(Cl)C=C1)(C(C=C)=O)C2=CC(F)=C(O[C@@H]3CC[C@@H](N)C3)C=C2
InChIKey: HJRLDGALXMTJAU-QULYPMOISA-N

Specifications

MW (average): 516.9130
Formula: C₂₄H₂₅ClF₄N₂O₄
CAS No.: 3106364-91-1
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃, 3 years; In solvent -20℃ 1 month;

Solubility

soluble in DMSO

Documents

References

[1]. Palisse A, et al. Structure-Based Discovery of a Series of Covalent, Orally Bioavailable, and Selective BFL1 Inhibitors. Journal of medicinal chemistry. 2024 Dec 26;67(24):22055-22079.

Same target

Search Bcl-2 Family

Same research area

Search Cancer